S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
NASDAQ:NVCN

Neovasc - NVCN Stock Forecast, Price & News

$7.48
-0.32 (-4.10%)
(As of 08/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$7.25
$7.80
50-Day Range
$4.90
$7.86
52-Week Range
$4.59
$21.56
Volume
11,649 shs
Average Volume
15,670 shs
Market Capitalization
$20.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$125.00

Neovasc MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,571.1% Upside
$125.00 Price Target
Short Interest
Healthy
0.55% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.25mentions of Neovasc in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.06 out of 5 stars

Medical Sector

601st out of 1,098 stocks

Surgical & Medical Instruments Industry

63rd out of 112 stocks

NVCN stock logo

About Neovasc (NASDAQ:NVCN) Stock

Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.

Analyst Upgrades and Downgrades

Separately, StockNews.com started coverage on Neovasc in a research report on Tuesday. They set a "sell" rating on the stock.

Neovasc Price Performance

Shares of NASDAQ:NVCN traded up $0.04 during mid-day trading on Tuesday, reaching $7.80. The company had a trading volume of 5,156 shares, compared to its average volume of 14,997. The company has a debt-to-equity ratio of 0.27, a quick ratio of 12.50 and a current ratio of 12.88. Neovasc has a one year low of $4.59 and a one year high of $21.56. The firm has a market cap of $21.14 million, a price-to-earnings ratio of -0.65 and a beta of 2.30. The business's 50-day simple moving average is $6.16 and its 200 day simple moving average is $9.36.

Neovasc (NASDAQ:NVCN - Get Rating) (TSE:NVC) last issued its quarterly earnings results on Thursday, May 12th. The medical equipment provider reported ($3.01) EPS for the quarter, missing analysts' consensus estimates of ($1.25) by ($1.76). Neovasc had a negative return on equity of 50.69% and a negative net margin of 1,192.20%. The company had revenue of $0.61 million during the quarter, compared to the consensus estimate of $0.80 million. On average, research analysts predict that Neovasc will post -5 earnings per share for the current fiscal year.

Receive NVCN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neovasc and its competitors with MarketBeat's FREE daily newsletter.

NVCN Stock News Headlines

Neovasc (NVCN) to Release Earnings on Thursday
A Full Year Of Recommended Stock Picks Now 60% Off
Get Unlimited Access to Motley Fool Stock Advisor Join over 1 million investors, who like you, are on their investment journey with us. A library of expert stock recommendations are only a few clicks away. Join today and start potentially multiplying your net worth.
Neovasc (NASDAQ:NVCN) Now Covered by Analysts at StockNews.com
He's Giving Away His Ultimate Dividend Package FOR FREE!
Marc Lichtenfeld, Author of Get Rich with Dividends, is giving away his Ultimate Dividend Package, Including Details on His #1 Dividend Stock... the Safest 8% Dividend in the World... the Top Three "Extreme Dividend" Stocks... and Much, Much More. For Free. pixel
Form 6-K NEOVASC INC For: Jul 26 - StreetInsider.com
Neovasc (NASDAQ:NVCN) Coverage Initiated at StockNews.com
Neovasc Inc - Baystreet.ca
See More Headlines
Receive NVCN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neovasc and its competitors with MarketBeat's FREE daily newsletter.

NVCN Company Calendar

Last Earnings
5/12/2022
Today
8/09/2022
Next Earnings (Confirmed)
8/11/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NVCN
Employees
49
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$125.00
High Stock Price Forecast
$125.00
Low Stock Price Forecast
$125.00
Forecasted Upside/Downside
+1,571.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-24,890,000.00
Net Margins
-1,192.20%
Pretax Margin
-1,211.86%

Debt

Sales & Book Value

Annual Sales
$2.55 million
Book Value
$19.31 per share

Miscellaneous

Free Float
N/A
Market Cap
$20.25 million
Optionable
Not Optionable
Beta
2.30

Key Executives

  • Mr. Fredericus A. Colen (Age 70)
    Pres, CEO & Director
    Comp: $2.59M
  • Mr. Christopher Clark B.A. (Age 50)
    BA (Honours), C.A., CA, PgD, CFO & Corp. Sec.
    Comp: $1.09M
  • Mr. William Reed Little (Age 51)
    Chief Operating Officer
    Comp: $1.2M
  • Mr. John Christopher Panton (Age 55)
    Chief Quality Officer
    Comp: $388.98k
  • Sarah Marie-Hodgson Gallagher
    VP of Clinical Affairs













NVCN Stock - Frequently Asked Questions

Should I buy or sell Neovasc stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Neovasc in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" NVCN shares.
View NVCN analyst ratings
or view top-rated stocks.

What is Neovasc's stock price forecast for 2022?

1 Wall Street research analysts have issued 1 year target prices for Neovasc's shares. Their NVCN share price forecasts range from $125.00 to $125.00. On average, they predict the company's stock price to reach $125.00 in the next twelve months. This suggests a possible upside of 1,502.6% from the stock's current price.
View analysts price targets for NVCN
or view top-rated stocks among Wall Street analysts.

How has Neovasc's stock price performed in 2022?

Neovasc's stock was trading at $11.7150 at the start of the year. Since then, NVCN stock has decreased by 33.4% and is now trading at $7.80.
View the best growth stocks for 2022 here
.

When is Neovasc's next earnings date?

Neovasc is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our NVCN earnings forecast
.

How can I listen to Neovasc's earnings call?

Neovasc will be holding an earnings conference call on Thursday, August 11th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Neovasc's earnings last quarter?

Neovasc Inc. (NASDAQ:NVCN) released its quarterly earnings data on Thursday, May, 12th. The medical equipment provider reported ($3.01) EPS for the quarter, missing analysts' consensus estimates of ($1.25) by $1.76. The medical equipment provider had revenue of $0.61 million for the quarter, compared to the consensus estimate of $0.80 million. Neovasc had a negative trailing twelve-month return on equity of 50.69% and a negative net margin of 1,192.20%.

When did Neovasc's stock split?

Neovasc's stock reverse split before market open on Friday, April 29th 2022. The 1-25 reverse split was announced on Friday, April 29th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of Neovasc own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neovasc investors own include Biopharmx (BPMX), Allstate (ALL), Amicus Therapeutics (FOLD), Synergy Pharmaceuticals (SGYP), Rexahn Pharmaceuticals (REXN), Heat Biologics (HTBX), Protalix BioTherapeutics (PLX), Palatin Technologies (PTN), Amarin (AMRN).

What is Neovasc's stock symbol?

Neovasc trades on the NASDAQ under the ticker symbol "NVCN."

How do I buy shares of Neovasc?

Shares of NVCN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Neovasc's stock price today?

One share of NVCN stock can currently be purchased for approximately $7.80.

How much money does Neovasc make?

Neovasc (NASDAQ:NVCN) has a market capitalization of $21.14 million and generates $2.55 million in revenue each year. The medical equipment provider earns $-24,890,000.00 in net income (profit) each year or ($12.00) on an earnings per share basis.

How many employees does Neovasc have?

Neovasc employs 49 workers across the globe.

How can I contact Neovasc?

Neovasc's mailing address is Suite 5138 - 13562 Maycrest Way, RICHMOND A1, V6V 2J7. The official website for the company is www.neovasc.com. The medical equipment provider can be reached via phone at (604) 270-4344, via email at investors@neovasc.com, or via fax at 604-270-4384.

This page (NASDAQ:NVCN) was last updated on 8/9/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.